A new blood test could help diagnose cancer cases earlier. Researchers from the University of Southern California developed a blood test to detect early onset ovarian cancer. The test, called OvaPrint, is described as a 'cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer,' according to the report published in the journal Clinical Cancer Research.
The test is 'highly sensitive and specific' for women experiencing symptoms, the results showed — with the potential for future use in asymptomatic cases. High-grade serous ovarian carcinoma is often diagnosed at later stages, the research states. It is the most common and lethal type of ovarian cancer, according to the National Institutes of Health. As of now, the most effective way to identify a pelvic mass is through surgery, followed by pathological testing.
There are still no effective screening tools in women who are asymptomatic, the report stated. The researchers were able to develop OvaPrint by testing samples to distinguish ovarian cancers from benign masses. OvaPrint achieved a 'positive predictive value of 95% and a negative predictive value of 88% for discriminating HGSOC from benign masses, surpassing other commercial tests,' the researchers reported.
The researchers are looking into a follow-up study to validate results, according to Medical Press. This validation could lead to OvaPrint's commercial availability within the next two years.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: physorg_com - 🏆 388. / 55 Read more »
Source: physorg_com - 🏆 388. / 55 Read more »